| melanoma {BayesPPDSurv} | R Documentation |
Melanoma Clinical Trials E1684 and E1690
Description
A dataset for the E1684 clinical trial (1996) and the E1690 clinical trial (2000) conducted to assess the utility of interferon alfa-2b (INF) as an adjuvant therapy following surgery for deep primary or regionally metastatic melanoma. This dataset contains subjects in disease stage four only, i.e., regional lymph node recurrence at any interval after appropriate surgery for primary melanoma of any depth.
Usage
melanoma
Format
A data frame with 381 rows and 5 variables:
- study
study number (1684 or 1690)
- failtime
time to relapse in years
- rfscens
censoring indicator for time to relapse (0 = did not relapse, 1 = relapsed)
- trt
treatment (1 if IFN and 0 if Observation)
- stratum
stratum index (1 if number of positive nodes <= 2 and 2 if number of positive nodes >= 3
Source
Kirkwood, J. M., J. G. Ibrahim, V. K. Sondak, J. Richards, L. E. Flaherty, M. S. Ernstoff, T. J. Smith, U. Rao, M. Steele, and R. H. Blum (2000, Jun). High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial e1690/s9111/c9190. Journal of Clinical Oncology 18 (12), 2444–2458.
Kirkwood, J. M., M. H. Strawderman, M. S. Ernstoff, T. J. Smith, E. C. Borden, and R. H. Blum (1996). Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the eastern cooperative oncology group trial est 1684. Journal of Clinical Oncology 14, 7–17.